| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | NOT_YET_RECRUITING | PHASE3 | 2025-10-15 | 2029-02 | 2028-11 |
| NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) | RECRUITING | PHASE2 | 2025-07-25 | 2029-07-15 | 2027-07-15 |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | RECRUITING | PHASE3 | 2025-02-07 | 2028-04-05 | 2027-05-02 |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2025-01-29 | 2025-06-11 | 2025-06-11 |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | RECRUITING | PHASE3 | 2024-11-25 | 2029-10-31 | 2027-01-31 |
| NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2024-11-13 | 2028-06-29 | 2028-05-29 |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | RECRUITING | PHASE1 | 2024-08-28 | 2026-01-31 | 2025-09-30 |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | RECRUITING | PHASE3 | 2024-08-13 | 2028-01 | 2028-01 |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2024-05-14 | 2028-05 | 2028-05 |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | RECRUITING | PHASE3 | 2024-02-05 | 2037-11 | 2037-11 |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2024-01-29 | 2025-08-18 | 2025-08-18 |
| NCT06057038 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-11-24 | 2026-12-26 | 2026-03-26 |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | WITHDRAWN | PHASE2 | 2023-10-01 | 2028-06-01 | 2028-04-01 |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | TERMINATED | PHASE1, PHASE2 | 2023-09-21 | 2025-02-05 | 2025-02-05 |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | RECRUITING | PHASE1, PHASE2 | 2023-03-15 | 2026-12-31 | 2026-09-15 |
| NCT05491317 | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-03-08 | 2025-11 | 2025-11 |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-03-06 | 2027-07-31 | 2026-01-30 |
| NCT05578976 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-02-08 | 2029-12 | 2027-06 |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | RECRUITING | PHASE1, PHASE2 | 2022-12-07 | 2027-09 | 2027-06 |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-10-24 | 2025-10-21 | 2025-10-21 |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | TERMINATED | PHASE1, PHASE2 | 2022-10-04 | 2024-05-24 | 2024-05-24 |
| NCT05206357 | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-10-04 | 2028-11 | 2028-11 |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-09-20 | 2029-12 | 2029-12 |
| NCT05451810 | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-08-17 | 2027-03 | 2027-03 |
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | RECRUITING | PHASE2 | 2022-06-14 | 2032-11 | 2032-11 |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-03-10 | 2025-04 | 2025-04 |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-12-13 | 2026-03-26 | 2026-03-26 |
| NCT05117242 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-10-27 | 2027-03 | 2024-12-02 |
| NCT04937153 | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | COMPLETED | PHASE1 | 2021-06-15 | 2024-10-01 | 2024-10-01 |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | TERMINATED | PHASE1, PHASE2 | 2021-03-09 | 2025-07-31 | 2025-06-30 |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-01-13 | 2028-04 | 2025-12 |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | RECRUITING | PHASE1, PHASE2 | 2020-11-25 | 2029-08 | 2029-06 |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-11-03 | 2028-09-30 | 2028-09-30 |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-08-20 | 2027-09 | 2027-09 |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2020-07-15 | 2021-10-29 | 2021-10-29 |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | TERMINATED | PHASE1, PHASE2 | 2020-03-13 | 2023-07-28 | 2022-11-21 |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-09-17 | 2026-11 | 2025-12 |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-05-14 | 2026-02 | 2025-04-01 |
| NCT03913741 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies | COMPLETED | PHASE1, PHASE2 | 2019-02-27 | 2021-10-30 | 2020-08-14 |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-06-26 | 2029-01 | 2029-01 |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2018-04-30 | 2021-10-12 | 2021-10-12 |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-11-23 | 2021-11-12 | 2021-11-12 |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | COMPLETED | PHASE1, PHASE2 | 2010-03 | 2011-10 | 2011-07 |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | TERMINATED | PHASE1, PHASE2 | 2008-09 | 2010-10 | 2010-10 |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer | TERMINATED | PHASE1, PHASE2 | 2008-04 | 2009-04 | 2009-04 |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | COMPLETED | PHASE2 | 2008-01 | 2011-08 | 2011-08 |
| NCT00460551 | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer | TERMINATED | PHASE2 | 2007-04 | 2008-10 | 2008-10 |
| NCT00401401 | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer | TERMINATED | PHASE1, PHASE2 | 2006-12 | 2010-10 | 2010-10 |
| NCT00382031 | Zalutumumab in Patients With Non-curable Head and Neck Cancer | COMPLETED | PHASE3 | 2006-11 | 2011-08 | 2009-12 |
| NCT00093041 | Zalutumumab in Head and Neck Cancer | COMPLETED | PHASE1, PHASE2 | 2003-12-01 | 2005-01-12 | 2005-01-12 |
| NCT00071084 | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. | COMPLETED | PHASE2 | 2003-05-27 | 2004-06-29 | 2004-06-29 |
| NCT00071071 | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | COMPLETED | PHASE2 | 2003-04-30 | 2004-05-05 | 2004-05-05 |
| NCT00042406 | Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker | TERMINATED | PHASE2, PHASE3 | 2002-03-04 | 2003-03-31 | 2003-03-31 |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors | WITHDRAWN | PHASE2 | | | |